NFX focuses on pre-seed and seed-stage startups with network effects at their core, with a dedicated NFX Bio practice backing scientist-founders at the intersection of biology, computation, and technology.
About NFX
NFX is a San Francisco-based seed-stage venture firm built around the thesis that network effects are the dominant moat in software businesses, with a partner team of repeat founders and a strong brand in the seed ecosystem. The firm has historically backed marketplace, platform, and software companies where the model is genuinely network-effects-driven, and it has selective exposure to digital health, biotech, and AI-for-biology through its bio-focused fund and adjacent strategies. Healthcare exposure is meaningful, particularly through the firm’s biotech and bio-AI activities, and is selective in mainstream digital health and healthtech. AI focus is real and central, with strong interest in AI-native applications across consumer, enterprise, and biology categories. Stage is Seed, with check sizes plausibly in the USD 1M to USD 3M range as a lead or strong co-investor with significant follow-on capacity through later rounds. This is the wrong door for healthcare services, capital-intensive devices, or any business where network effects are not a core part of the moat. It is a strong fit for healthcare software, marketplace, and bio-AI founders whose business genuinely compounds through network effects and who want a high-signal seed lead. Entry path is the firm’s signal application platform and warm introductions from portfolio founders; the firm reads inbound and the partner team is responsive when the network-effects thesis is genuine.
Founder reviews
Other portfolio companies
Companies in NFX's portfolio not currently in our directory.
Team
Pitch / review this investor
Have you raised from NFX? Founders only — share your honest experience (anonymous OK, moderated before publishing).